Attached files
| file | filename |
|---|---|
| EX-32.1 - EXHIBIT 32.1 - Synthetic Biologics, Inc. | tm205312d1_ex32-1.htm |
| EX-31.1 - EXHIBIT 31.1 - Synthetic Biologics, Inc. | tm205312d1_ex31-1.htm |
| EX-21 - EXHIBIT 21 - Synthetic Biologics, Inc. | tm205312d1_ex21.htm |
| EX-4.16 - EXHIBIT 4.16 - Synthetic Biologics, Inc. | tm205312d1_ex4-16.htm |
| 10-K - FORM 10-K - Synthetic Biologics, Inc. | tm205312-1_10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Synthetic Biologics, Inc.
Rockville, MD
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (Nos. 333-180562, 333-188219, 333-156973, 333-206267, 333-207327, 333-203323 , 333-226500 and 333-224728), the Registration Statement on Form S-1 (Nos. 333-227400) and Form S-8 (Nos. 333-192355, 333-170858, 333-148764, 333-206268, 333-213388, 333-220401, 333-227668 and 333-233959) of Synthetic Biologics, Inc. of our report dated February 20, 2020 relating to the consolidated financial statements, which appears in this Form 10-K. Our report on the consolidated financial statements contains an explanatory paragraph regarding the Company's ability to continue as a going concern.
| /s/ BDO USA, LLP | |
| BDO USA, LLP | |
| Potomac, Maryland | |
| February 20, 2020 |